Clinical Gastroenterology and Hepatology · 2024 · 16 citations · 38 references
MedicineOncologyPharmacotherapyCancer ControlHepatologyMolecular VirologyAntiviral TherapyHepatocellular CarcinomaInterferon-based TherapyLiver DiseaseViral HepatitisViral Hepatitis TreatmentAntiviral TreatmentChronic Hepatitis B - Associated CarcinomaChronic Hepatitis Virus PersistenceChronic Viral HepatitisHepatocellular Carcinoma Risk ReductionPrimary Outcome AnalysisTenofovir TherapyViral Load Assessment
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain. METHODS: IU/mL) who initiated entecavir or tenofovir treatment. The primary outcome was on-treatment HCC incidence, stratified by baseline HBV viral load as a categorical variable. RESULTS: IU/mL, who exhibited the lowest HCC risk. CONCLUSION: Baseline viral load showed a significant, non-linear, parabolic association with HCC risk during antiviral treatment in noncirrhotic patients with CHB. Early initiation of antiviral treatment based on HBV viral load may help prevent irreversible HCC risk accumulation in patients with CHB.
38